Differential influences of Fc gamma receptor blocking on the effects of certolizumab pegol and infliximab on human monocytes
- 14 August 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 28 (3) , 506-512
Abstract
Objectives: To compare the effects of certolizumab pegol (CZP) and infliximab (IFX) on human monocytes.Methods: Highly purified monocytes from healthy donors were cultured with CZP, IFX, control IgG1, or polyethylene glycol (PEG) at pharmacological attainable concentrations in culture medium with 10% autologous normal human serum (NHS) or with fetal bovine serum (FBS) for 24h, after which the supernatants were replaced by fresh culture medium containing LPS. After additional 24h of incubation, the supernatants were assayed for TNF- and IL-6. In some experiments, the cells were harvested after 1h of stimulation with LPS for analysis of mRNA for TNF- by quantitative PCR.Results: Pre-incubation of monocytes with CZP or IFX reduced the production of TNF- in subsequent cultures stimulated by LPS in a dose-dependent manner. The suppressive effects of IFX on the TNF- production were significantly diminished, but those of CZP were rather enhanced, in cultures with autologous NHS compared with in cultures with FBS. Addition of IgG, but not IgG F(ab)(2) fragments, significantly inhibited the suppressive effects of IFX on the production of TNF- and IL-6, whereas either IgG or IgG F(ab)(2) fragments had no significant influences on the suppressive effects of CZP. Furthermore, pre-incubation with CZP or IFX significantly inhibited the expression of mRNA for TNF- and IL-6 in monocytes compared with PEG or IgG.Conclusion: These results indicate that the mechanism of action of CZP is different from that of IFX. Thus, CZP suppresses the production of proinflammatory cytokines independently of Fc receptors, whereas the suppressive effects of IFX on human monocytes are almost totally dependent on the interaction with Fc receptors.Keywords
Funding Information
- Parents’ Association, Kitasato University School of Medicine
This publication has 23 references indexed in Scilit:
- Profile of certolizumab and its potential in the treatment of psoriatic arthritisDrug Design, Development and Therapy, 2013
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD studyAnnals of the Rheumatic Diseases, 2009
- TNFα blockade in human diseases: Mechanisms and future directionsClinical Immunology, 2008
- Developing a New Generation of TNF Antagonists for the Treatment of Rheumatoid ArthritisMolecular Interventions, 2003
- Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-αNature, 1997
- A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cellsNature, 1997
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNFCell, 1988
- Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxinNature, 1984